RameshRenganMDPhD

Medical Director, Seattle Cancer Care Alliance Proton Therapy Center; Professor of Radiation Oncology, University of Washington School of Medicine; Associate Member, Fred Hutchinson Cancer Research Center

Join to view full profile

Dr. Rengan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Rengan's full profile

Already have an account?

Office
1959 NE Pacific St
Seattle, WA 98195
Phone+1 206-598-4100

Summary

Dr. Rengan is a board-certified radiation oncologist who specializes in radiation treatment for lung, melanoma, and prostate cancer.

Dr. Rengan was previously the Chief of Thoracic Service and Associate Director of Clinical Operations for the Department of Radiation Oncology at the University of Pennsylvania, where he worked extensively with proton therapy. He completed his residency in radiation oncology at Memorial Sloan-Kettering Cancer Center in 2006 and earned his medical degree and Ph.D. in biological chemistry from University of Michigan Medical School and Rackham School of Graduate Studies in 2001.

Dr. Rengan’s philosophy of “patients come first” fits well with his areas of research, which involve the development of clinical and translational (bench-to-bedside) initiatives designed to improve clinical outcomes in cancer. His research interests also include understanding the biology of cancer in order to make radiation treatment more effective and using radiation as a tool to stimulate the immune system to target the cancer.

Education & Training

Memorial Sloan Kettering Cancer CenterResidency, Radiation Oncology, 2002 - 2006
St Mary's Hospital and Medical CenterInternship, Internal Medicine, 2001 - 2002
University of Michigan Medical SchoolClass of 2001

Certifications & Licensure

WA State Medical License 2013 - 2025
PA State Medical License 2006 - 2024
CA State Medical License 2021 - 2023
NY State Medical License 2002 - 2015
NJ State Medical License 2006 - 2013
American Board of Radiology Radiation Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012

Clinical Trials

Nelfinavir, Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery Start of enrollment: 2007 Jun 01
Completed
Phase 1, Phase 2
Flaxseed Supplement in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Undergoing Chemotherapy and Radiation Therapy Start of enrollment: 2007 Dec 01
Terminated
Phase 1
Proton Beam Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Can Be Removed By Surgery Start of enrollment: 2010 Jan 01
Completed
Phase 1, Phase 2
Proton Beam Radiation With Concurrent Chemotherapy and Nelfinavir for Inoperable Stage III Non Small Cell Lung Cancer (NSCLC) Start of enrollment: 2010 Mar 01
Terminated
Phase 2
Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma Start of enrollment: 2014 Mar 01
Terminated
Phase 2
Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer Start of enrollment: 2017 Jun 09
Terminated
Phase 2
ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-Immunotherapy Start of enrollment: 2021 Dec 10
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

2 citations
Preclinical Ultra-High Dose Rate (FLASH) Proton Radiation Therapy System for Small Animal Studies.
Ning Cao, Danielle P Johnson Erickson, Eric C Ford, Robert C Emery, Marissa Kranz
Advances in Radiation Oncology. 2024-03-01
Commissioning a clinical proton pencil beam scanning beamline for pre-clinical ultra-high dose rate irradiations on a cyclotron-based system.
Jatinder Saini, Danielle P Johnson Erickson, François Vander Stappen, Matt Ruth, Sunan Cui
Frontiers in Oncology. 2024-01-01
Focal therapy for oligometastatic and oligoprogressive renal cell carcinoma: a narrative review.
August C Anderson, Joel Ho, Evan T Hall, Raquibul Hannan, Jay J Liao
Future Oncology. 2024-01-01

Lectures

Long-term results of a phase I/II trial of nelfinavir with concurrent chemoradiotherapy for locally advanced non-small cell lung cancer.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Press Mentions

Clinical Oncology Findings from Seattle Cancer Care Alliance (SCCA) Clinicians to Be Featured at the 2021 ASCO Annual MeetingJune 3rd, 2021
Low-Dose Radiotherapy for Lung Inflammation in Severe COVID-19November 5th, 2020
Can Low-Dose Radiotherapy Treat COVID-19-Related Pneumonia?November 3rd, 2020
Join now to see all

Committees

Committee member, National Cancer Institute’s Radiation and Immune Modulation Working Group
Associate Senior Editor, Journal “Advances in Radiation Oncology."